Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) just unveiled an update.
Qyuns Therapeutics Co., Ltd. announced the acceptance by the China Securities Regulatory Commission (CSRC) of its application for the proposed conversion of 17,322,400 domestic shares into H shares for full circulation and listing on the Stock Exchange. The process is subject to further regulatory procedures and finalization of the implementation plan. Stakeholders are advised to be cautious in their dealings with the company’s shares as the conversion and listing process continues, with additional announcements to follow.
More about Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. is a company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company focuses on developing innovative therapeutic solutions and has a market position that involves handling shares on the Hong Kong Stock Exchange.
YTD Price Performance: 1.49%
Average Trading Volume: 40,331
Technical Sentiment Consensus Rating: Strong Buy
For an in-depth examination of 2509 stock, go to TipRanks’ Stock Analysis page.